[ad_1]
On June 13, the Supreme Court of the United States unanimously ruled to dismiss the case challenging the use of mifepristone, a drug commonly employed in medical abortions, affirming that the plaintiffs lacked the necessary standing for the lawsuit.
The opinion for the case, known as FDA v. Alliance for Hippocratic Medicine, was penned by Justice Brett Kavanaugh. He concluded that the plaintiffs, who are staunchly pro-life, do not have Article III standing because they neither prescribe nor use mifepristone and are therefore not directly regulated by the FDA’s actions concerning the drug.
Kavanaugh’s writing explained, “Plaintiffs express legal, moral, ideological, and policy opposition to mifepristone’s prescription and use by others. Still, they stand as unregulated entities challenging the FDA’s regulation of other parties.”
The ruling followed oral arguments in March, where it became apparent that the Court’s concern was more about the standing of the pro-life doctors’ coalition, who disputed the loosening of the FDA regulations for mifepristone, rather than the legality of the FDA’s decisions.
The contested regulations included methods of distributing mifepristone through mail, a decision the FDA defends, citing minimal risk to women in early pregnancy stages.
Dr. Ingrid Skop, a seasoned OB-GYN and director of medical affairs at the Charlotte Lozier Institute, expressed her disappointment with the Court’s decision not to hold the FDA accountable for “reckless” loosening of safety standards surrounding the distribution of abortion drugs.
In contrast, Rachel O’Leary Carmona of Women’s March welcomed the Supreme Court’s decision, emphasizing the significance of maintaining access to what she states is a “safe and effective” method for abortion.
Mifepristone was first approved by the FDA over two decades ago and acts by inhibiting progesterone, a hormone crucial for maintaining pregnancy. When coupled with misoprostol, it constitutes a regimen used to induce early abortions and occasionally to manage early pregnancy losses.
With more than half of the abortions in the U.S. being chemical rather than surgical, according to CDC data, this ruling upholds the status quo concerning the availability of mifepristone across the country.
This case was a significant abortion-related case on the Court’s agenda following the overturning of prior abortion precedents in 2022.
Reported by Kate Scanlon from OSV News. Keep up with her coverage from Washington on X (formerly Twitter) @kgscanlon.
[ad_2]
FAQs about the Supreme Court Mifepristone Ruling
What is mifepristone and how is it used?
Mifepristone is a medication that blocks the hormone progesterone, which is necessary for maintaining pregnancy. It is often used in combination with misoprostol to induce a medical abortion during the early weeks of pregnancy. It can also be prescribed for managing early pregnancy loss.
Why was mifepristone challenged in the Supreme Court?
The challenge arose from a coalition of pro-life doctors regarding the FDA’s decision to ease regulations on mifepristone—particularly the ability to obtain it through mail—arguing that it violated safety standards.
What was the basis of the Supreme Court’s decision?
The decision, written by Justice Brett Kavanaugh, stated that the plaintiffs lacked Article III standing as they were neither directly regulated by the FDA’s regulation of mifepristone nor did they prescribe or use the medication themselves.
What does this ruling mean for the availability of mifepristone?
The Supreme Court’s unanimous ruling means that the current status of mifepristone’s availability, including distribution through mail, remains upheld. The drug will continue to be accessible to individuals seeking a medical abortion in the early stages of pregnancy.
Has the use of mifepristone increased over the years?
Yes, according to CDC data, over half of all abortions conducted in the U.S. are now chemical or medical abortions, indicating an increased use of medications like mifepristone for this purpose.
